Clinical Trials Logo

Pulmonary Artery Hypertension clinical trials

View clinical trials related to Pulmonary Artery Hypertension.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT06122922 Withdrawn - Clinical trials for Pulmonary Artery Hypertension

Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

The objective of this project is to determine how pulmonary vascular remodeling in Pulmonary Arterial Hypertension (PAH) at cellular and pathological level is associated with gas exchange physiology changes and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.

NCT ID: NCT02684786 Withdrawn - Clinical trials for Pulmonary Artery Hypertension

A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension

Start date: July 2016
Phase: Phase 1
Study type: Interventional

Pulmonary hypertension Group 2 (PH 2) associated with left-sided heart disease is relatively common, is associated with a poor prognosis, and unfortunately there are no proven medical treatments beyond attempts at correcting the left sided heart disease. Many PH 2 patients have evidence of active constriction of blood vessels from increased nerve traffic. Use of agents or procedures which produce a reversible chemical blockage of this nerve traffic have not been systematically tested in PH 2. The investigators will test whether acute interruption of sympathetic nervous system tone, which local anesthetic block of the stellate ganglion in the neck, will improve PH2, and also test whether the high blood pressure drug reserpine, which blocks sympathetic nerve activity, will do so during a one month trial period.